Judith G Villablanca1, Samuel L Volchenboum2, Hwangeui Cho3, Min H Kang3, Susan L Cohn2, Clarke P Anderson4, Araz Marachelian1, Susan Groshen5, Denice Tsao-Wei5, Katherine K Matthay6, John M Maris7, Charlotte E Hasenauer1, Scarlett Czarnecki1, Hollie Lai8, Fariba Goodarzian8, Hiro Shimada9, Charles Patrick Reynolds3. 1. Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California. 2. Department of Pediatrics, University of Chicago Comprehensive Cancer Center, Chicago, Illinois. 3. Cancer Center and Departments of Cell Biology & Biochemistry, Pediatrics, and Medicine, Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas. 4. City of Hope National Medical Center, Duarte, California. 5. Department of Preventative Medicine Statistics, Keck School of Medicine, University of Southern California, Los Angeles, California. 6. Department of Pediatrics, University of California San Francisco, San Francisco, California. 7. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 8. Department of Radiology, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California. 9. Department of Pathology and The Saban Research Institute, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND: Myeloablative therapy for high-risk neuroblastoma commonly includes melphalan. Increased cellular glutathione (GSH) can mediate melphalan resistance. Buthionine sulfoximine (BSO), a GSH synthesis inhibitor, enhances melphalan activity against neuroblastoma cell lines, providing the rationale for a Phase 1 trial of BSO-melphalan. PROCEDURES: Patients with recurrent/resistant high-risk neuroblastoma received BSO (3 gram/m(2) bolus, then 24 grams/m(2) /day infusion days -4 to -2), with escalating doses of intravenous melphalan (20-125 mg/m(2) ) days -3 and -2, and autologous stem cells day 0 using 3 + 3 dose escalation. RESULTS: Among 28 patients evaluable for dose escalation, one dose-limiting toxicity occurred at 20 mg/m(2) melphalan (grade 3 aspartate aminotransferase/alanine aminotransferase) and one at 80 mg/m(2) (streptococcal bacteremia, grade 4 hypotension/pulmonary/hypocalcemia) without sequelae. Among 25 patients evaluable for response, there was one partial response (PR) and two mixed responses (MRs) among eight patients with prior melphalan exposure; one PR and three MRs among 16 patients without prior melphalan; one stable disease with unknown melphalan history. Melphalan pharmacokinetics with BSO were similar to reports for melphalan alone. Melphalan Cmax for most patients was below the 10 μM concentration that showed neuroblastoma preclinical activity with BSO. CONCLUSIONS: BSO (75 gram/m(2) ) with melphalan (125 mg/m(2) ) is tolerable with stem cell support and active in recurrent/refractory neuroblastoma. Further dose escalation is feasible and may increase responses.
BACKGROUND: Myeloablative therapy for high-risk neuroblastoma commonly includes melphalan. Increased cellular glutathione (GSH) can mediate melphalan resistance. Buthionine sulfoximine (BSO), a GSH synthesis inhibitor, enhances melphalan activity against neuroblastoma cell lines, providing the rationale for a Phase 1 trial of BSO-melphalan. PROCEDURES: Patients with recurrent/resistant high-risk neuroblastoma received BSO (3 gram/m(2) bolus, then 24 grams/m(2) /day infusion days -4 to -2), with escalating doses of intravenous melphalan (20-125 mg/m(2) ) days -3 and -2, and autologous stem cells day 0 using 3 + 3 dose escalation. RESULTS: Among 28 patients evaluable for dose escalation, one dose-limiting toxicity occurred at 20 mg/m(2) melphalan (grade 3 aspartate aminotransferase/alanine aminotransferase) and one at 80 mg/m(2) (streptococcal bacteremia, grade 4 hypotension/pulmonary/hypocalcemia) without sequelae. Among 25 patients evaluable for response, there was one partial response (PR) and two mixed responses (MRs) among eight patients with prior melphalan exposure; one PR and three MRs among 16 patients without prior melphalan; one stable disease with unknown melphalan history. Melphalan pharmacokinetics with BSO were similar to reports for melphalan alone. Melphalan Cmax for most patients was below the 10 μM concentration that showed neuroblastoma preclinical activity with BSO. CONCLUSIONS: BSO (75 gram/m(2) ) with melphalan (125 mg/m(2) ) is tolerable with stem cell support and active in recurrent/refractory neuroblastoma. Further dose escalation is feasible and may increase responses.
Authors: G Dini; E Lanino; A Garaventa; D Rogers; S Dallorso; C Viscoli; E Castagnola; G Manno; M Brisigotti; C Rosanda Journal: J Clin Oncol Date: 1991-06 Impact factor: 44.544
Authors: T C Hamilton; M A Winker; K G Louie; G Batist; B C Behrens; T Tsuruo; K R Grotzinger; W M McKoy; R C Young; R F Ozols Journal: Biochem Pharmacol Date: 1985-07-15 Impact factor: 5.858
Authors: S X Skapek; A F VanDellen; D P McMahon; D G Postels; O W Griffith; D D Bigner; H S Friedman Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333
Authors: Julia A Messina; Su-Chun Cheng; Benjamin L Franc; Martin Charron; Barry Shulkin; Bao To; John M Maris; Gregory Yanik; Randall A Hawkins; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2006-12 Impact factor: 3.167
Authors: Alessia Ongaro; Agnese Pellati; Monica De Mattei; Francesca De Terlizzi; Carlo R Rossi; Luca G Campana Journal: Anticancer Drugs Date: 2015-03 Impact factor: 2.248
Authors: Julie R Park; Rochelle Bagatell; Susan L Cohn; Andrew D Pearson; Judith G Villablanca; Frank Berthold; Susan Burchill; Ariane Boubaker; Kieran McHugh; Jed G Nuchtern; Wendy B London; Nita L Seibel; O Wolf Lindwasser; John M Maris; Penelope Brock; Gudrun Schleiermacher; Ruth Ladenstein; Katherine K Matthay; Dominique Valteau-Couanet Journal: J Clin Oncol Date: 2017-05-04 Impact factor: 44.544
Authors: Isaac S Harris; Jennifer E Endress; Jonathan L Coloff; Laura M Selfors; Samuel K McBrayer; Jennifer M Rosenbluth; Nobuaki Takahashi; Sabin Dhakal; Vidyasagar Koduri; Matthew G Oser; Nathan J Schauer; Laura M Doherty; Andrew L Hong; Yun Pyo Kang; Scott T Younger; John G Doench; William C Hahn; Sara J Buhrlage; Gina M DeNicola; William G Kaelin; Joan S Brugge Journal: Cell Metab Date: 2019-02-21 Impact factor: 27.287
Authors: Minjong Lee; Ara Jo; Seulki Lee; Jong Bin Kim; Young Chang; Joon Yeul Nam; Hyeki Cho; Young Youn Cho; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Jung-Hwan Yoon; Yoon Jun Kim Journal: PLoS One Date: 2017-03-31 Impact factor: 3.240